Class II recall: Apollo Care, LLC: SEMAGLUTIDE 7.5mg (5mg/mL), Glycine 7.5 mg (5mg/mL), 1.5 mL Sterile Multi-Dose V
A Class II recall has been issued for Apollo Care, LLC's compounded SEMAGLUTIDE 7.5mg (5mg/mL) with Glycine 7.5mg (5mg/mL), packaged as 1.5 mL sterile multi-dose vials for subcutaneous injection (NDC 71170-721-01). The recall notice states the issue involves the presence of particulate matter identified as nylon/polyamide and silk/proteinaceous-type material.
Most relevant for: patients using compounded semaglutide for weight loss or glycemic control who received vials from Apollo Care, LLC
Read the original at FDA Drug Enforcement ReportsSummary written by an AI model from the source text and dated by the source's publication date. Check the original before acting on it. How MedFollow selects and summarizes updates.
Informational only. Not medical advice. Not a substitute for clinical judgment. Always consult current guidelines and your own clinical judgment.
Specialties
More family medicine updates
- Long-Acting Injectable HIV Therapy Noninferior for Adherence ChallengesOct 15, 2026
- 8-week sofosbuvir-velpatasvir regimen non-inferior to 12 weeks for HCVSep 30, 2026
- Lean MASLD shows milder histology but similar mortality outcomesSep 30, 2026
- Oral GLP-1 orforglipron shows cardiovascular non-inferiority to insulin glargineSep 30, 2026
- Retatrutide produces substantial weight loss in phase 3 diabetes trialSep 29, 2026